News & PR



July 25th 2018   Baylor College of Medicine launches the ERGENT Study using CLIRINX

The Baylor College of Medicine has launched their new study called Early "Recognition of Genetic Epilepsy in Neonates" (ERGENT). Seizures in babies can be the result of a birth injury, but in about 5-10% of instances, they are caused by a specific genetic change. Research has allowed doctors to learn features that are common in babies with genetic epilepsy. ERGENT is designed to test whether those features can identify babies with genetic epilepsy very soon after birth, so their treatment may be targeted to the specific cause.
Study PI: Edward C. Cooper MD PhD



July 20th 2018   Luirie Children's goes "live" with the Early Life Epilepsy Natural History Project using CLIRINX

Luirie Children's goes "live" with the Early Life Epilepsy Natural History Project using the CLIRINX system. This study that aims to define and identify the areas where children with early life epilepsies face difficulties and how these issues evolve over time. The information that comes from this project can be used to inform parents, educate providers, and facilitate trials of new therapies in the future. The project also strives to answer the questions that parents of children with early life epilepsies have and to establish a platform that future studies can utilize in defining the different challenges children with epilepsy face and the impact on the family.
Study PI: Dr. Anne Berg, Ph.D.



May 8th 2018   CLIRINX selected as a Finalist for the Bio-IT World Best Practices Award 2018

CLIRINX has been selected as a finalist for the Bio-IT World Best Practices Award 2018 for its implementation of CLIRINX at the Baylor College of Medicine in the catagories of Knowledge Management and Clinical/Health IT. Bio-IT World has held the Best Practices awards since 2003, highlighting outstanding examples of technology innovation in the life sciences, from basic R&D to translational medicine. The Award honors excellence in bioinformatics, basic and clinical research, and IT frameworks for biology and drug discovery.



Feb 15th 2018   CLIRINX secures contract to develop bioinformatics tools for research into Sudden Cardiac Death.

CLIRINX has secured a contract to develop bioinformatics tools for Northwestern Medicine (USA) as part of their precision medicine initiative. These tools will be used to investigate genetic variants associated with heart rhythm (channelopathies) and myocardial function (cardiomyopathies), which cause approximately a quarter of all cases of sudden unexplained death (SUD).
Study PI: Gregory Webster, M.D.



Jan 24th 2018   CLIRINX wins major "SME Award"

CLIRINX has won at the "SME Awards 2018" in the category "New Product/Service". These awards acknowledge the achievements of small to medium sized businesses in Ireland. [link]



Jan 5th 2018   CLIRINX signs major contract with Lurie Children's Hospital of Chicago (USA)

CLIRINX has signed a major 3 year contract with Lurie Children's Hospital of Chicago (Illinois, USA) to implement CLIRINX EDC and AI for their precision medicine initiative and rare disease natural history studies. The scope of the contract includes CLIRINX web-based electronic data collection and artificial intelligence systems, cloud-based hosting on Amazon AWS (using TerraAlto AWS Consultants) and informatics support. "Lurie will now have a state-of-the-art IT system to improve the quality of their research data and reduce data collection costs significantly,” says Mr Gerry Nesbitt, CEO, CLIRINX. "By implementing the CLIRINX system, Lurie researchers can potentially improve people's lives by finding new cures and better treatments for human diseases."
Study PI: Dr. Anne Berg, Ph.D.



Dec 4th 2017   CLIRINX selected for "Genetic Epilepsy in Neonates Study" at Baylor College of Medicine (Texas, USA)

The Baylor College of Medicine (Texas, USA) has selected CLIRINX as their IT platform for a new epilepsy study. The title of this study is "Early Recognition of Genetic Epilepsy in Neonates Study (ERGENT)", and aims to overcome delays in genetic screening by demonstrating the feasibility of early diagnosis of early onset genetic encephalopathies, especially KCNQ2 and SCN2A related epileptic encephalopathy.
Study PI: Edward Cooper, M.D., Ph.D.



Dec 1st 2017   CLIRINX shortlisted as "Innovator of the Year" at SFA National Small Business Awards 2018

CLIRINX is delighted to announce that it has been shortlisted as a finalist in the category "Innovator of the Year" in the SFA National Small Business Awards 2018. This award is run by the Small Firms Association. CLIRINX will feature at the SFA Small Business Showcase in the RDS in Feb 2018, and the winners will be announced in Mar 2018 at the Awards Gala Ceremony.


Nov 8th 2017    CLIRINX is a Finalist in the SME Awards 2017

CLIRINX has been selected as a finalist in this year's SME Awards 2017. We are a finalist in 2 categories, "New Business" and "New Product". These awards acknowledge the achievements of small to medium sized businesses in Ireland. [link]


July 11th 2017    CLIRINX is a Finalist in the DatSci Awards 2017

Delighted to announce that CLIRINX (Clinical Research IT) is a finalist in this year's DatSci Awards in the category "Best use of Data Science in a Start-up" for its electronic data collection and artificial intelligence (AI) solutions in clinical research. The DatSci awards aim to acknowledge the value contributed by Data Science to the success of businesses and community, bringing data scientists together to celebrate Ireland’s amazing accomplishments in Data Science. [link]


June 12th 2017    Children's Hospital Colorado picks CLIRINX for new Infantile Spasms Study

Children's Hospital Colorado has picked CLIRINX for study management and electronic data collection on a new pediatric clinical research study. The title of the research study is "A Novel Approach to Infantile Spasms: Combined Cosyntropin Injectable Suspension, 1 mg/mL and Vigabatrin Induction Therapy". This 5-year study will enroll ~400 infants and children with new onset Infantile spasms from 15+ medical centers. Infantile spasms, also know as West syndrome, occurs in 2-5 per 10,000 live births and represent a severe epileptic encephalopathy in infancy.
Study PI: Kelly Knupp, M.D.
ClinicalTrials.gov NCT03347526


May 18th 2017    CLIRINX wins Silver award at Bank of Ireland Startup Awards 2017

CLIRINX has won the Silver award at the Bank of Ireland Startup Awards 2017 in the category "Healthcare Startup". These awards are Ireland’s premier awards program for early stage Irish businesses, and recognise and reward the spirit of entrepreneurship in Ireland. This year has been a fantastic year for CLIRINX, and this award gives further recognition to our commitment to help bring the best IT solutions to the medical research community. [link]


April 26th 2017    CLIRINX nominated as finalist in Bank of Ireland Startup Awards 2017

CLIRINX has been selected as a finalist in the Bank of Ireland Startup Awards 2017 in the category "Healthcare Startup". These awards are Ireland’s premier awards program for early stage Irish businesses, and recognise and reward the spirit of entrepreneurship in Ireland. The winners will be announced on May 18th. This year has been a fantastic year for CLIRINX, and this award nomination gives further recognition to our commitment to help bring the best IT solutions to the medical research community. [link]



Mar 24th 2017   CLIRINX involved in Pediatric Neurology publication: "Optimizing the Diagnosis and Management of Dravet Syndrome"

CLIRINX is proud to announce that it was involved in the medical publication "Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel". This major paper was published in Pediatric Neurology 68 (2017) 18-34 and is available for download by clicking here. The objectives of this study were to establish standards for early, cost-effective, and accurate diagnosis; optimal therapies for seizures; and recommendations for evaluation and management of comorbidities for children and adults with Dravet syndrome. This study used CLIRINX for electronic data collection.



Mar 22nd 2017   CLIRINX can help with planned NIH research budget cuts!

With the planned reduction of 18% to the National Institutes of Health budget, CLIRINX is the ideal partner to provide all the IT for your research studies. Our sofware products are the best electronic data collection tools available for academic medical research, which we provide for free, and our research IT expertise is second to none. We help your research studies collect the best research data possible and eliminate IT costs to provide massive cost savings. Contact us today for as demo and discuss how CLIRINX can help your research studies in these uncertain times.



Mar 15th 2017   CLIRINX launches a new Artificial Intelligence product for Medical Research

CLIRINX has added a new Artificial Intelligence (AI) product to its Clinical Research IT software suite. The Expert System, named "CX Expert" can be used to help with decision-making and solve complex problems in medical research. It consists of an inference engine and can support multiple user-defined knowledge bases. The inference engine uses backward chaining (depth first) methods and accommodates fuzzy logic and formulas in IF conditions. CLIRINX is the only medical research EDC system that incorporates an expert system. Some examples of its current uses include "determining the patient's seizure type", "patient eligibility" and "managing adverse events".



Mar 2nd 2017   CLIRINX wins "Emerging New Business" Award at SFA Awards 2017

CLIRINX was a winner in the "Emerging New Business" category of the Small Firms Association Business Awards 2017. These awards recognize the achievement and excellence in small business. The award was presented at a gala event in the RDS on March 1st 2017 by the Minister for Employment and Small Business, Pat Breen, TD, and SFA Chair, Sue O'Neill. [link] [photo]



Mar 1st 2017   CLIRINX profiled in Irish Independent SFA Supplement

As a winner at the SFA National Small Business Awards 2017 (Emerging New Business), CLIRINX was profiled in the 2017 Small Firms Association business supplement in the Irish Independent. The companies showcased were from a wide range of business sectors, and have demonstrated entrepreneurship, product and market innovation, and a commitment to business growth. The awards were presented at a gala event in the RDS on March 1st 2017 by the Minister for Employment and Small Business, Pat Breen, TD. [link]



Feb 1st 2017   CLIRINX exhibits at the SFA Small Business Showcase in the RDS

As a winner at the SFA National Small Business Awards 2017 (Emerging New Business), CLIRINX had the opportunity to exhibit at the SFA Small Business Showcase 2017 held at the RDS, Dublin. A showcase of positivity, this event highlighted the entrepreneurship, innovation and achievements of small enterprises in Ireland. The conference was officially opened by the Minister for Jobs, Enterprise & Innovation, Mary Mitchell O’Connor, TD.



Dec 5th 2016   CLIRINX/KCNQ2 Poster presented at American Epilepsy Society 2016

Poster #3.329 "An Informatics Infrastructure for KCNQ2 Encephalopathy Research Including a Patient Registry, Database, Curation Platform, and Website" was presented at the American Epilepsy Society Annual Meeting 2016 in Houston, TX. This infrastructure was built using the CLIRINX Clinical Research IT platform. [link]



Dec 5th 2016   CLIRINX shortlisted as finalist at SFA National Small Business Awards 2017

CLIRINX is delighted to announce that it has been shortlisted as a finalist for "Best Emerging New Business" at the SFA National Small Business Awards 2017 [link] . This award is run by the Small Firms Association. CLIRINX will feature at the SFA Small Business Showcase in the RDS on Feb 1st 2017, and the winners will be announced on Mar 1st 2017 at the Awards Gala Ceremony.



Nov 11th 2016  CLIRINX shortlisted as finalist at Irish MedTech Excellence Awards 2016

CLIRINX is delighted to announce that it has been shortlisted as a finalist for "Emerging Medtech Company of the Year" at the Irish MedTech Excellence Awards 2016. This award is run by The Irish Medical Devices Association, Enterprise Ireland and IDA Ireland.



Oct 8th 2016   CLIRINX attends KCNQ2 Cure’s 2016 Family & Professional Summit

Gerry Nesbitt attended KCNQ2 Cure’s 2016 Family & Professional Summit in Silver Springs, Maryland. This 3-day event was designed to unite all groups committed to improving the lives of those with KCNQ2 Epilepsy – including families, caregivers, clinicians, researchers and professionals in the pharmaceutical industry.



Mar 2nd 2016   Rett Syndrome Research Trust selects CLIRINX for electronic data collection

The Rett Syndrom Research Trust (RSRT) is now using CLIRINX for electronic data collection on their academic medical research projects. Over 30 data collection forms will be imported from RedCap, and the application will be rolled-out to users across multiple clinical sites.



Jan 10th 2016   Baylor College of Medicine selects CLIRINX for KCNQ2/3 Research

The Baylor College of Medicine is now using CLIRINX for the Rikee.org research project (Rational Intervention for KCNQ2/3 Epileptic Encephalopathy Project). This group investigates new treatments and cures for KCNQ2/3 related illnesses. In addition, we will custom develop an integrated KCNQ2/3 gene variant pathogenity and severity calculator.



July 10th 2015   Dravet Foundation selects CLIRINX for electronic surveys

The Dravet Foundation will be using CLIRINX for electronic surveys. Large data collection surveys will be sent in 3 phases to physicians and family members in the US and Canada.The data collected will be analysed by investigators at the Mayo Clinic and Lure Children's.




© CLIRINX Ltd.

T: EU +353-86-4186512 / US +1 412 5671172    E: info@clirinx.com    W: http://www.clirinx.com

Privacy Policy & Website Disclaimer